Objectives: The aim of the network ResoVerneuil is to improve global health, management and quality of care in HS patients

Introduction: ResoVerneuil is a French French-speaking network created in 2015 and dedicated to any medical or paramedical practionner interested in the field of hidradenitis suppurativa (HS).

Materials / method: • Improving care pathway and management of HS patients
• Develop research in the field of HS
• Favor information and experience sharing, and dissemination of knwoledge
• Breaking prejudices conveyed by HS by raising awareness of health care providers, general public and decision-makers

Results: The network has near 200 members, with either public or liberal activities, including dermatologists and surgeons.

Conclusion: ResoVerneuil offers a town-hospital network as close as possible to the patients. It also supports clinical research by facilitating patients recruitment.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To improve the knowledge about the principles, the indications and the techniques of surgical treatment of hidradenitis suppurativa (HS)

Introduction: HS remains poorly recognized by practionners adn as such may be treated unefficiently. Surgery is one of the major treatment option and deseves to be performed by aware practitionners

Materials / method: Presentation of a 12 year experience of surgery for HS, higlighted by a literature review

Results: participants to this session will have practical data to choose how and when operate the patients and how to develop a surgical activity in the field of HS

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Understand the main features of the disease, the challenges with the treatments and how to choose between antibiotics and biotherapies.

Introduction: As HS is both an infectious and auto-inflammatory disease, treatments can be both antibiotics and anti-cytokines antibodies, mainly anti-TNF-alpha. Surgery is also an important option which will be discussed in another session.

Materials / method: Review of the literature ans experience of RESOVERNEUIL in France (french network for HS).

Results: The main protocol is the association of rifampicin / clindamycin. Many protocols have derived now from this historical one: rifampicin / ofloxacin; rifampicin / moxifloxacin / metronidazole in induction phase, and then cotrimoxazole in maintenance phase. For biologics, the anti-TNF adalumimab in the only one to have an agreement in Europe. But many new molecules are under investigation: anti-IL-17 (secukinumab), anti-IL-23 (guselkumab), anti-complement fractions (anti-C5a). The field of treatments is now increasing every year.

Conclusion: The best option depends on the main clinical presentation: purulent or rather inflammatory phase. In a same patient, treatment can change depending on a particular phase of the disease. It remains anyway a multidisciplinary approach.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To evaluate the effectiveness, safety and tolerability of intralesional photodynamic therapy (I-PDT) in the management of HS. Also, to assess the effect of this technique on the different areas treated

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent skin condition which has no cure nowadays . Photodynamic therapy (PDT) has been used for more than ten years with different results because of the depth of the disease. Intralesional PDT, could resolve this limitation.

Materials / method: Review of our experience in more than 60 patients with HS treated with intralesional PDT. This technique consists of the use of a photosensitizer gel (5-aminolevulinic acid 2%) introduced inside the fistulas or abscesses to treat to be incubated for two hours. Later a 630nm laser light irradiates the lessions. Finally patients are reevaluated with different HS scales to identify the response of the technique.

Results: In case series of 38 patients 29 achieved complete response , and 18 of them needed only one session and 8 patients had persistence of lessions. Difference between basal and final Hidradenitis Severity Score showed a significant reduction of 24.5 points (p<0.001). Dermatology Life Quality Index scores reached a reduction of 10 points (p<0.001)

Conclusion: Intralesional-PDT could be an excellent local treatment for HS lesions. It has achieved high rate of long-term remission and without relevant complications.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability